Koya Medical is a technology company.
Koya Medical has raised $70.0M across 4 funding rounds.
Koya Medical has raised $70.0M in total across 4 funding rounds.
Koya Medical has raised $70.0M in total across 4 funding rounds.
Koya Medical's investors include Cota Capital, Highbury Group, Khosla Ventures, OrbiMed, Pear VC, Tencent Holdings, WndrCo LLC, Chris Schaepe, David Chen, Farzad Nazem, Laszlo Bock, 5AM Ventures.
Koya Medical is a medtech company developing wearable active compression therapies for lymphedema and venous disorders, with its flagship Dayspring system enabling patient mobility during treatment.[1][2][3] Founded in 2018, it serves patients with chronic edema and healthcare providers, addressing limitations of traditional pneumatic compression by offering nonpneumatic, app-controlled devices that support daily activities and improve adherence.[2][3][4] The company has shown strong growth, raising $26M in Series B funding in 2022 to expand commercialization, publishing clinical data like the NILE trial, securing FDA clearances and CMS billing codes, and opening a 35,000 sq ft Dallas HQ in 2025 to scale manufacturing amid rising demand.[1][2][3][4]
Koya Medical was founded in 2018 by Andy Doraiswamy, Ph.D., who serves as president and CEO, inspired by a personal journey with post-cancer lymphedema that highlighted gaps in existing treatments.[2][3] Doraiswamy's background in transformative healthcare drove the creation of patient-centric platforms starting with the Dayspring system, initially FDA-cleared for upper extremities in 2020 and lower extremities in 2021, followed by U.S. commercial launch.[1][2] Early traction included CMS billing codes in 2022 and $26M Series B funding to accelerate expansion, with pivotal moments like the NILE head-to-head clinical trial validating efficacy over legacy devices.[2][4] The company evolved from an Oakland R&D hub to a Dallas-based HQ in 2025, reflecting revenue-driven scaling.[3][6]
Koya Medical stands out in vascular health through these key features:
Koya Medical rides the wave of home-based vascular care innovation, targeting the millions affected by lymphedema and venous diseases amid rising chronic condition prevalence and demand for patient-empowering medtech.[2][3][7] Timing aligns with post-pandemic shifts to ambulatory treatments, FDA/CMS support accelerating adoption, and medtech funding for mobility-focused devices.[1][2] Market forces like aging populations and lymphedema's lifelong needs favor non-invasive, adherent solutions over bulky alternatives, positioning Koya to influence lymphatic/venous care ecosystems through clinical evidence and comprehensive pipelines from clinic to home.[3][4][8] By redefining compression as wearable tech, it bridges gaps in vascular health, inspiring similar patient-centric medtech advancements.[7][9]
Koya Medical's trajectory points to accelerated growth via Dayspring commercialization, pipeline expansions for new indications, and global scaling from its Dallas hub.[2][3] Trends like AI-personalized therapies, telehealth integration, and value-based care will shape its path, amplifying clinical outcomes and market penetration.[4][8][9] Its influence may evolve into a vascular health platform leader, potentially through partnerships or further funding, transforming lives for chronic edema patients as it began with a founder's personal story.[2][3]
Koya Medical has raised $70.0M across 4 funding rounds. Most recently, it raised $30.0M Series C in November 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Nov 1, 2023 | $30.0M Series C | Cota Capital, Highbury Group, Khosla Ventures, OrbiMed, Pear VC, Tencent Holdings, WndrCo LLC, Chris Schaepe, David Chen, Farzad Nazem, Laszlo Bock | |
| Feb 1, 2022 | $26.0M Series B | 5AM Ventures, Arboretum Ventures, F-Prime Capital Partners, HealthQuest Capital, Telegraph Hill Partners | |
| Jan 1, 2021 | $11.0M Series A | 5AM Ventures, Arboretum Ventures, F-Prime Capital Partners, HealthQuest Capital, Telegraph Hill Partners | |
| Jun 1, 2019 | $3.0M Seed | Locus Ventures, Taher Haveliwala |